Introduction
============

Cerebral palsy (CP) is a group of non-progressive motor impairment syndromes caused by lesions during early brain development that often include cognitive deficits and musculoskeletal dysfunction \[[@B1],[@B2]\]. The prevalence of CP -- around 2 to 3 cases per 1,000 live births -- has been stable over the past 30 years \[[@B3]\]. CP has become the leading cause of childhood disability in both developing and developed countries \[[@B4],[@B5]\], but the vast majority of the underlying pathogenic factors behind the development of CP are still unknown. Risk factors for CP have been categorized as prenatal, perinatal, and postnatal, but the majority of the risk factors -- about 70% to 80% -- occur prenatally \[[@B6]\]. Prenatal inflammation, such as intrauterine inflammation, is believed to be an important causal factor of adverse neurological outcomes \[[@B7]\], and an abnormal cytokine response has been suggested to be a common pathway for inducing brain injury \[[@B8]\].

Interleukin-6 (IL-6) is a pro-inflammatory cytokine that responds to intrauterine infection by inducing further increases in cytokine production \[[@B8]\]. Studies have shown that IL-6 is linked to clinical chorioamnionitis and preterm birth and that there is a three-fold increased risk for the development of periventricular leukomalacia (PVL) in preterm infants \[[@B9],[@B10]\]. The *IL-6* single nucleotide polymorphism (SNP) rs1800795 (G-174C) was reported to be associated with disabling brain injury but not cognitive development in 148 children who were born at less than 32 weeks gestational age in the UK \[[@B9]\]. Additionally, a population-based case-control study including 334,333 infants showed that rs1800795 is a risk factor for CP among term and near-term infants who were born at more than 36 weeks gestational age in the US \[[@B11],[@B12]\]. However, with comparable gestational age distributions in CP patients and control groups, conflicting results showed no association between CP and rs1800795 in 144 very preterm infants who were born at less than 32 weeks gestational age in Croatia \[[@B13]\]. The conflicting results might be based on differences in sample size or could indicate that the effect of *IL-6* gene function in the development of CP might be influenced by ethnicity or gestational age. Based on a replicate genetic study on SNPs from different regions of the *IL-6* gene, we have previously reported that the SNP rs2069837 is associated with male spastic CP in the Chinese Han population. To further confirm the risk factors associated with SNPs and to validate the regulation of IL-6 by the SNPs \[[@B10]\], we used a larger sample size to analyze five polymorphisms from different regions of the *IL-6* gene and combined this with a plasma IL-6 protein assay to evaluate the importance of IL-6 in the etiology of CP.

Methods
=======

Subjects
--------

The study population consisted of 713 CP patients (219 girls (30.7%) and 494 boys (69.3%) with a mean age ± SD of 19.1 ± 14.9 months) chosen from centers for CP rehabilitation in the Third Affiliated Hospital of Zhengzhou University and Zhengzhou Children's Hospital from 1 July 2010 to 31 May 2012 (Table [1](#T1){ref-type="table"}). Of these, 87 CP patients (54 boys (62.1%) and 33 girls (37.9%) with a mean age ± SD of 19.9 ± 14.1 months) were selected for the serum IL-6 assay (Table [2](#T2){ref-type="table"}). The 753 healthy control participants (262 girls (34.8%) and 491 boys (65.2%) with a mean age ± SD of 19.6 ± 18.5 months) were chosen from the Child Healthcare Departments at the same hospitals during the same period. Of these healthy controls, 77 (63 boys (81.8%) and 14 girls (18.2%) with a mean age ± SD of 19.8 ± 12.4 months) were selected for the serum IL-6 assay. Blood samples were collected into tubes containing EDTA by skilled nurses on the second day of being hospitalized. Plasma was separated by centrifugation (1,500 × *g* for 15 min) at room temperature within 2 hours after being collected. DNA was obtained from the remaining blood components from the same sample. All the prepared samples were immediately stored at −70°C. All subjects were Han Chinese from the Henan Province, and written informed consent to participate in this study was provided by the children's parents. Child neurologists diagnosed and classified the CP by clinical examination or by using medical records, including brain imaging, according to the guidelines proposed by the "Surveillance of CP in Europe" network \[[@B14]\]. Children in either the CP or control group with myopathy or metabolic anomalies were excluded from the analysis. For the serum IL-6 assay, the age of the selected children ranged from 5 months to 36 months. Children with cough, fever, acute respiratory illness, or any other any indications of infection within the past 3 months were excluded. Because of the genetic factors and familial factors that are associated with CP, we ensured that the controls had no familial relationships with the patients and did not have neurological symptoms. Approval for the study was obtained from the ethics committee of Zhengzhou University and the Medical Academy of Henan Province (201201002) in accordance with the Declaration of Helsinki.

###### 

Sample description for gene polymorphism analysis

  **Characteristic**      **CP cases**   **Control**               
  ---------------------- -------------- ------------- ------------ ---------
  **Type of CP**                                                        
  Spastic CP               456 (64.0)      325/131         --         --
  Non-spastic CP           257 (36.0)      169/88          --         --
  Total                    713 (100)       494/219     753 (100)    491/262
  **Gestational age**                                                   
  Term (≥37 weeks)         496 (69.6)      338/158     742 (98.5)   481/261
  Preterm (\<37 weeks)     217 (30.4)      156/61       11 (1.5)     10/1
  Total                    713 (100)       494/219     753 (100)    491/262
  **Birth weight**                                                      
  ≥2,500 g                 552 (77.4)      390/162     731 (97.1)   475/256
  \<2,500 g                161 (22.6)      104/57       22 (2.9)     16/6
  Total                    713 (100)       494/219     753 (100)    491/262
  **Birth asphyxia**                                                    
  No asphyxia              484 (67.9)      326/158     741 (98.4)   482/259
  Asphyxia                 229 (32.1)      168/61       12 (1.6)      9/3
  Total                    713 (100)       494/219     753 (100)    491/262
  **Complication**                                                      
  With PVL                 75 (10.5)        56/19          --         --
  Without PVL              638 (89.5)      438/200         --         --
  With MR                  274 (38.4)      185/89          --         --
  Without MR               439 (61.6)      309/130         --         --
  With HIE                 342 (48.0)      245/97          --         --
  Without HIE              371 (52.0)      249/122         --         --
  **Maternal factors**                                                  
  PROM                     88 (12.3)        62/26       14 (1.9)     11/3
  No PROM                  625 (87.7)      432/193     739 (98.1)   480/259
  TPL                       57 (8.0)        42/15       23 (3.1)     17/6
  No TPL                   656 (92.0)      452/204     730 (96.9)   474/256
  PIH                       35 (4.9)        23/12       14 (1.9)     12/2
  No PIH                   678 (95.1)      471/207     739 (98.1)   479/260

CP, cerebral palsy; M, male; F, female; PVL, periventricular leukomalacia; MR, mental retardation; HIE, hypoxic ischemic encephalopathy; PROM, premature rupture of membrane; TPL, threatened premature labor; PIH, pregnancy-induced hypertension.

###### 

Sample description for cytokine quantification

  **Characteristic**      **CP cases**   **Control**              
  ---------------------- -------------- ------------- ----------- -------
  **Type of CP**                                                      
  CP with spastic          58 (68.2)        35/23         --        --
  CP without spastic       27 (31.8)        19/8          --        --
  Total                     85 (100)        54/31      75 (100)    62/13
  **Gestational age**                                                 
  Term (≥37 weeks)         56 (65.9)        41/15      70 (93.3)   57/13
  Preterm (\<37 weeks)     29 (34.1)        13/16       5 (6.7)     5/0
  Total                     85 (100)        54/31      75 (100)    62/13
  **Birth weight**                                                    
  ≥2,500 g                 61 (71.8)        43/18      71 (94.7)   59/12
  \<2,500 g                24 (28.2)        11/13       4 (5.3)     3/1
  Total                     85 (100)        54/31      75 (100)    62/13
  **Birth asphyxia**                                                  
  No asphyxia              51 (60.0)        32/19      73 (97.3)   61/12
  Asphyxia                 34 (40.0)        22/12       2 (2.7)     1/1
  Total                     85 (100)        54/31      75 (100)    62/13
  **Complication**                                                    
  With PVL                 17 (20.0)        11/6          --        --
  Without PVL              68 (80.0)        43/25         --        --
  With MR                  62 (72.9)        37/25         --        --
  Without MR               23 (27.1)        17/6          --        --
  With HIE                 31 (36.5)        20/11         --        --
  Without HIE              54 (63.5)        34/20         --        --
  **Maternal factors**                                                
  PROM                     19 (22.4)        8/11        7 (9.3)     5/2
  No PROM                  66 (77.6)        46/20      68 (90.7)   57/11
  TPL                      20 (23.5)        15/5       15 (20.0)   11/4
  No TPL                   65 (76.5)        39/26      60 (80.0)   51/9
  PIH                       8 (9.4)          5/3        6 (8.0)     5/1
  No PIH                   77 (90.6)        49/28      69 (92.0)   57/12

CP, cerebral palsy; M, male; F, female; PVL, periventricular leukomalacia; MR, mental retardation; HIE, hypoxic ischemic encephalopathy; PROM, premature rupture of membrane; TPL, threatened premature labor; PIH, pregnancy-induced hypertension.

The database of medical records contains information on CP risk factors, such as birth asphyxia, symptoms concomitant with CP, such as mental retardation (MR), neonatal complications, such as PVL, and on hypoxic-ischemic encephalopathy (HIE). In addition, the records contain information on maternal factors such as premature rupture of membrane (PROM), pregnancy-induced hypertension (PIH), and threatening premature labor (TPL). Asphyxia was diagnosed using the criteria of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists, and newborns were included when at least three of the four criteria were met \[[@B15]\]. MR was identified based on a score of less than 70 on the Bayley Scales measurement of mental development index \[[@B16]\]. PVL was defined as parenchymal densities or lucencies around the ventricles during ultrasound examination of the head performed any time after 14 days post-birth \[[@B17]\], and this was further confirmed by MRI. Diagnosis of HIE required a combination of parameters that are indicative of metabolic acidosis within the first hours after birth. These include low umbilical cord blood pH (\<7.0), a base deficit of over 12 mEq/L, and evidence of a need for respiratory support starting in the first minutes after birth with low Apgar scores at and beyond 5 min after birth. The diagnosis of PROM was based on pooling of amniotic fluid in the vagina, amniotic fluid ferning patterns, and a positive nitrazine test \[[@B18]\]. PIH was diagnosed and classified according to the criteria recommended by the American Congress of Obstetricians and Gynecologists, including a systolic blood pressure of 140 mmHg or higher or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 6 h apart occurring after 20 weeks of gestation in a pregnant woman with previously normal blood pressure and without detectable urinary protein \[[@B19]\]. TPL was based on at least one of the following having occurred during pregnancy: the mother was admitted to the hospital prenatally with an episode of TPL, the mother received antenatal steroids or tocolytics, or a note was made on the delivery room chart that there was a history of TPL during the pregnancy \[[@B20]\].

Polymorphism selection
----------------------

A total of five SNPs (rs1800796, rs2069837, rs2066992, rs2069840, and rs10242595) of the *IL-6* gene whose minor allele frequencies in the Chinese Han population are more than 0.1 were selected from the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>) and the hapmap human SNP database (<http://www.hapmap.org>). All of rs2069837, rs2066992 in the second intron, and rs2069840 in the third intron are tag SNPs. rs1800796 and rs10242595 are located in the upstream and downstream regions of the *IL-6* gene, respectively.

Genotyping
----------

Genomic DNA was prepared from venous blood using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen Biosciences, Union City, CA, USA) according to the manufacturer's instructions. Probes and primers were designed by the SEQUENOM online tools (<https://www.mysequenom.com>) and the sequences are available upon request. After the amplification of polymorphism-spanning fragments by multiplex polymerase chain reaction (PCR), the genotyping was performed with the Sequenom MassARRAY SNP genotyping platform (Sequenom, San Diego, CA, USA). The person who analyzed the genotype results was blinded to the clinical data.

IL-6 quantification
-------------------

Blood samples were collected using EDTA as an anti-coagulant. The samples were centrifuged at 1,500 × *g* for 15 min at room temperature, and plasma was aliquoted and stored at −70°C. Before the assay, the frozen samples were thawed completely at room temperature, mixed well by vortexing, and centrifuged to remove precipitated material. IL-6 was assayed together with IL-8, IL-10, IL-17, TNF-α, or IFN-γ by using the Milliplex Human Cytokine/Chemokine Kits (Millipore, Billerica, MA, USA) according to the manufacturer's instructions on a Luminex 200IS System (Luminex Corporation, Austin, TX, USA). Quality control was performed between the plates by using the two controls provided in the kit and representative samples from both CP patients and controls run on all the plates. The assay was completed on the same day by the same person. The plate variation was 6.94% in this assay. IL-6 levels were calculated using the Beadview software package (Upstate, Temecula, CA, USA) and expressed as pg/mL. The detection limit for IL-6 was 0.3 pg/mL.

Statistical analysis
--------------------

For gene analysis, the Hardy-Weinberg equilibrium (HWE) test was performed on the allele and genotype frequency analysis using the SHEsis online software platform (<http://analysis.bio-x.cn>). Linkage disequilibrium was measured using standardized D', and the discrepancies in allele and genotype frequencies at single loci between patients and controls were compared using a Monte Carlo simulation strategy. The numbers of observations for each haplotype were compared using χ^2^ tests. The relative risk was approximated by the estimate of the odds ratio (OR). All ORs were adjusted for age and sex using logistic regression models. For each OR, a 95% confidence interval (CI) was calculated. For IL-6 cytokine analysis, the Student's unpaired *t*-test was used. Data groups with unequal variances were analyzed using the Mann-Whitney U-test. All reported *P* values were two-tailed and statistical significance was set at *P* \<0.05. The Statistical Package for the Social Sciences (SPSS version 19.0) and Graphpad Prism 6.0 software package (version 6.0 for Windows, Graphpad, La Jolla, CA, USA) were used for all statistical analyses. For all comparisons, multiple testing on each individual SNP was corrected by the SNPSpD program (<http://gump.qimr.edu.au/general/daleN/matSpD/>), which is based on the linkage disequilibrium information.

Results
=======

Overall analysis
----------------

The genotypic distribution of the five selected SNPs in the controls was in HWE. There were no differences in allele or genotype frequencies between the total population of CP patients (n = 713) and total population of controls (n = 753) for any of the five genetic polymorphisms (Table [3](#T3){ref-type="table"}). Computation of D' indicated a strong linkage disequilibrium between these SNP markers (D' \>0.8) (Table [4](#T4){ref-type="table"}). A haplotype analysis of all five SNPs between the CP and control subjects was performed (those with a haplotype frequency \<0.03 were excluded from the analysis), and three common haplotypes were built. No differences in the haplotypes were found between CP cases and controls (data not shown).

###### 

Allele and genotype distribution of the five selected SNPs in cerebral palsy patients and controls

               **Group**      **Allele frequency**   ***P*value**    **Genotype frequency**  ***P*value**   **Hardy-Weinberg equilibrium**                   
  ------------ -------------- ---------------------- -------------- ------------------------ -------------- -------------------------------- ------- ------- ---
  rs1800796                   C                      G                                       C/C            C/G                              G/G               
  Case         977 (0.690)    439 (0.310)            0.256                347 (0.490)        283 (0.400)    78 (0.110)                       0.300    0.081  
  Control      992 (0.670)    488 (0.330)            334 (0.451)          324 (0.438)        82 (0.111)     0.797                                            
  rs2069837                   A                      G                                       A/A            A/G                              G/G               
  Case         1138 (0.807)   272 (0.193)            0.062                469 (0.665)        200 (0.284)    36 (0.051)                       0.144    0.018  
  Control      1134 (0.779)   322 (0.221)            448 (0.615)          238 (0.327)        42 (0.058)     0.169                                            
  rs2066992                   G                      T                                       G/G            G/T                              T/T               
  Case         441 (0.311)    977 (0.689)            0.389                 77 (0.109)        287 (0.405)    345 (0.487)                      0.316    0.140  
  Control      483 (0.326)    999 (0.674)            77 (0.104)           329 (0.444)        335 (0.452)    0.775                                            
  rs2069840                   C                      G                                       C/C            C/G                              G/G               
  Case         1300 (0.913)   124 (0.087)            0.503                591 (0.830)        118 (0.166)    3 (0.004)                        0.787    0.258  
  Control      1346 (0.906)   140 (0.094)            607 (0.817)          132 (0.178)        4 (0.005)      0.265                                            
  rs10242595                  A                      G                                       A/A            A/G                              G/G               
  Case         1255 (0.891)   153 (0.109)            0.435                560 (0.795)        135 (0.192)    9 (0.013)                        0.498    0.789  
  Control      1279 (0.882)   171 (0.118)            569 (0.785)          141 (0.194)        15 (0.021)     0.079                                            

###### 

The linkage disequilibrium among the SNPs

     **D'/r**^**2**^   **rs1800796**   **rs2069837**   **rs2066992**   **rs2069840**   **rs10242595**
  ------------------- --------------- --------------- --------------- --------------- ----------------
       rs1800796                           0.884           0.981           0.971           0.899
       rs2069837           0.463                           0.903           0.998           0.777
       rs2066992           0.948           0.497                           0.986           0.912
       rs2069840           0.203           0.026           0.211                           0.949
      rs10242595           0.228           0.025           0.235           0.704              

The standardized D' values are shown above the diagonal, and the r^2^ values are shown below the diagonal.

Subgroup analysis
-----------------

Subgroup analysis of SNPs was performed according to sex, gestational age, birth weight, birth asphyxia, subtypes of CP, pregnancy complications, and maternal factors. Significant differences in allele frequencies were observed between CP patients (n = 494) and controls (n = 491) in males for rs2069837 (OR = 1.334, 95% CI = 1.073--1.659, *P* = 0.009, *P* = 0.027 after SNPSpD correction) (Table [5](#T5){ref-type="table"}), but there were no differences in these SNP allele/genotype frequencies between CP patients and controls in females (data not shown).

###### 

Allele and genotype distribution of the five selected SNPs in male cerebral palsy cases and controls

               **Group**     **Allele frequency**   ***P*value**        **Genotype frequency**  ***P*value**   **Hardy-Weinberg equilibrium**                       
  ------------ ------------- ---------------------- ------------------ ------------------------ -------------- -------------------------------- ----------- ------- ---
  rs1800796                  C                      G                                           C/C            C/G                              G/G                   
  Case         678 (0.690)   304 (0.310)            0.092                    242 (0.493)        194 (0.395)    55 (0.112)                       0.113        0.093  
  Control      631 (0.655)   333 (0.345)            206 (0.427)              219 (0.454)        57 (0.118)     0.917                                                
  rs2069837                  A                      G                                           A/A            A/G                              G/G                   
  Case         790 (0.808)   188 (0.192)            **0.009**^**a**^         326 (0.667)        138 (0.282)    25 (0.051)                       **0.041**    0.044  
  Control      718 (0.759)   228 (0.241)            279 (0.590)              160 (0.338)        34 (0.072)     0.101                                                
  rs2066992                  G                      T                                           G/G            G/T                              T/T                   
  Case         303 (0.309)   677 (0.691)            0.119                     53 (0.108)        197 (0.402)    240 (0.490)                      0.159        0.193  
  Control      330 (0.342)   634 (0.658)            55 (0.114)               220 (0.456)        207 (0.429)    0.764                                                
  rs2069840                  C                      G                                           C/C            C/G                              G/G                   
  Case         901 (0.914)   85 (0.086)             0.646                    411 (0.834)        79 (0.160)     3 (0.006)                        0.742        0.704  
  Control      877 (0.908)   89 (0.092)             396 (0.820)               85 (0.176)        2 (0.004)      0.253                                                
  rs10242595                 A                      G                                           A/A            A/G                              G/G                   
  Case         870 (0.895)   102 (0.105)            0.304                    391 (0.805)        88 (0.181)     7 (0.014)                        0.578        0.426  
  Control      838 (0.880)   114 (0.120)            372 (0.782)               94 (0.197)        10 (0.021)     0.168                                                

^a^After the SNPSpD correction, the *P* value is 0.027.

Spastic CP was the main type of CP seen in this study population. Differences in allele frequencies were observed between spastic CP patients (n = 456) and controls (n = 753) for rs2069837, but the difference disappeared after SNPSpD correction (data not shown). Further analysis according to the sex of the CP patients revealed significant differences in allele and genotype frequencies between male spastic CP patients (n = 325) and controls (n = 491) for rs1800796, rs2069837, and rs2066992, but the differences for rs1800796 and rs2066992 disappeared after SNPSpD correction (Table [6](#T6){ref-type="table"}), which was similar to our previous analysis. Haplotype analysis for rs1800796, rs2069837, and rs2066992 showed that the haplotypes "CAT" and "GGG" (rs1800796, rs2069837, and rs2066992) were strongly associated with male spastic CP patients (haplotypes with a frequency \<0.03 were excluded from the analysis) (Table [7](#T7){ref-type="table"}).

###### 

Allele and genotype distributions of the SNPs in male spastic cerebral palsy patients and controls

                **Group**     **Allele frequency**   ***P*value**        **Genotype frequency**  ***P*value**   **Hardy-Weinberg equilibrium**                         
  ------------- ------------- ---------------------- ------------------ ------------------------ -------------- -------------------------------- ------------- ------- -------
  rs1800796                   C                      G                                           C/C            C/G                              G/G                       
  Spastic       458 (0.709)   188 (0.291)            **0.022**                169 (0.523)        120 (0.372)    34 (0.105)                       **0.027**      0.073  
  Non-spastic   220 (0.655)   116 (0.345)            0.995                     73 (0.435)        74 (0.440)     21 (0.125)                       0.944          0.739  
                Control       631 (0.655)            333 (0.345)                                 206 (0.427)    219 (0.454)                      57 (0.118)             0.917
  rs2069837                   A                      G                                           A/A            A/G                              G/G                       
  Spastic       524 (0.816)   118 (0.184)            **0.007**^**a**^         220 (0.685)        84 (0.262)     17 (0.053)                       **0.024**      0.022  
  Non-spastic   266 (0.792)   70 (0.208)             0.223                    106 (0.631)        54 (0.321)     8 (0.048)                        0.457          0.740  
                Control       718 (0.759)            228 (0.241)                                 279 (0.590)    160 (0.338)                      34 (0.072)             0.101
  rs2066992                   G                      T                                           G/G            G/T                              T/T                       
  Spastic       189 (0.293)   455 (0.707)            **0.040**                 34 (0.106)        121 (0.376)    167 (0.519)                      **0.041**      0.092  
  Non-spastic   114 (0.339)   222 (0.661)            0.919                     19 (0.113)        76 (0.452)     73 (0.435)                       0.994          0.907  
                Control       330 (0.342)            634 (0.658)                                 55 (0.114)     220 (0.456)                      207 (0.429)            0.764
  rs2069840                   C                      G                                           C/C            C/G                              G/G                       
  Spastic       599 (0.924)   49 (0.076)             0.245                    276 (0.852)        47 (0.145)     1 (0.003)                        0.489          0.498  
  Non-spastic   302 (0.893)   36 (0.107)             0.440                    135 (0.799)        32 (0.189)     2 (0.012)                        0.496          0.947  
                Control       877 (0.908)            89 (0.092)                                  396 (0.820)    85 (0.176)                       2 (0.004)              0.253
  rs10242595                  A                      G                                           A/A            A/G                              G/G                       
  Spastic       575 (0.901)   63 (0.099)             0.192                    261 (0.818)        53 (0.166)     5 (0.016)                        0.444          0.235  
  Non-spastic   295 (0.883)   39 (0.117)             0.885                    130 (0.778)        35 (0.210)     2 (0.012)                        0.729          0.835  
                Control       838 (0.880)            114 (0.120)                                 372 (0.782)    94 (0.197)                       10 (0.021)             0.168

^a^After the SNPSpD correction, the *P* value is 0.021.

###### 

Estimated IL-6 haplotype frequencies

  **Haplotype**    **Case (frequency)**   **Control (frequency)**   ***P*value**   **OR \[95% CI\]**
  ---------------- ---------------------- ------------------------- -------------- ------------------------
  CAT              446.99 (0.705)         586.16 (0.634)            0.011^a^       1.331 \[1.068--1.659\]
  GGG              113.50 (0.179)         202.19 (0.219)            0.039          0.764 \[0.591--0.987\]
  Global results                                                    0.037           

Loci chosen for haplotype analysis: rs1800796, rs2069837, and rs2066992.

Haplotype frequency \<0.03 in both controls and cases have been dropped.

^a^After Bonferroni correction the *P* value is 0.033.

OR, odds ratio; CI, confidence interval.

PVL is common in preterm brain injury and is related to the development of CP. In this study, we found differences in genotype frequencies between CP patients with PVL (n = 56) and controls (n = 491) in males at rs1800796 and rs2066992 (Table [8](#T8){ref-type="table"}). The haplotype analysis of all five analyzed SNPs did not show significant differences between CP patients with PVL and control subjects in either males or females.

###### 

Allele and genotype distributions of the SNPs in male cerebral palsy (CP) patients with or without periventricular leukomalacia (PVL)

               **Group**     **Allele frequency**   ***P*value**        **Genotype frequency**  ***P*value**   **Hardy-Weinberg equilibrium**                              
  ------------ ------------- ---------------------- ------------------ ------------------------ -------------- -------------------------------- ------------------ ------- -------
  rs1800796                  C                      G                                           C/C            C/G                              G/G                            
  CP + PVL     80 (0.714)    32 (0.286)             0.206                     33 (0.589)        14 (0.250)     9 (0.161)                        **0.014**^**b**^    0.004  
  CP − PVL     598 (0.687)   272 (0.331)            0.136                    209 (0.480)        180 (0.414)    46 (0.106)                       0.272               0.437  
               Control       631 (0.655)            333 (0.345)                                 206 (0.427)    219 (0.454)                      57 (0.118)                  0.917
  rs2069837                  A                      G                                           A/A            A/G                              G/G                            
  CP + PVL     91 (0.812)    21 (0.188)             0.207                     39 (0.696)        13 (0.232)     4 (0.071)                        0.263               0.075  
  CP − PVL     699 (0.807)   167 (0.193)            **0.013**^**a**^         287 (0.663)        125 (0.289)    21 (0.048)                       0.057               0.131  
               Control       718 (0.759)            228 (0.241)                                 279 (0.590)    160 (0.338)                      34 (0.072)                  0.101
  rs2066992                  G                      T                                           G/G            G/T                              T/T                            
  CP + PVL     32 (0.286)    80 (0.714)             0.230                     9 (0.161)         14 (0.250)     33 (0.589)                       **0.013**^**c**^    0.004  
  CP − PVL     271 (0.312)   597 (0.688)            0.171                     44 (0.101)        183 (0.422)    207 (0.477)                      0.348               0.705  
               Control       330 (0.342)            634 (0.658)                                 55 (0.114)     220 (0.456)                      207 (0.429)                 0.764
  rs2069840                  C                      G                                           C/C            C/G                              G/G                            
  CP + PVL     105 (0.938)   7 (0.062)              0.554                     49 (0.875)        7 (0.125)      0 (0.000)                        0.554               0.618  
  CP − PVL     796 (0.911)   78 (0.890)             0.830                    362 (0.828)        72 (0.165)     3 (0.007)                        0.778               0.777  
               Control       877 (0.908)            89 (0.092)                                  396 (0.820)    85 (0.176)                       2 (0.004)                   0.253
  rs10242595                 A                      G                                           A/A            A/G                              G/G                            
  CP + PVL     99 (0.900)    11 (0.100)             0.543                     45 (0.818)        9 (0.164)      1 (0.018)                        0.821               0.500  
  CP − PVL     771 (0.894)   91 (0.106)             0.341                    346 (0.803)        79 (0.183)     6 (0.014)                        0.603               0.542  
               Control       838 (0.880)            114 (0.120)                                 372 (0.782)    94 (0.197)                       10 (0.021)                  0.168

^a^After the SNPSpD correction, the *P* value is 0.039.

^b^After the SNPSpD correction, the *P* value is 0.042.

^c^After the SNPSpD correction, the *P* value is 0.039.

According to gestational age at birth, the CP patients and controls were stratified as term or preterm CP cases. A difference in allele and genotype frequencies for the rs2069837 site was observed between term CP patients (n = 338) and term controls (n = 491) in males (Table [9](#T9){ref-type="table"}), but no difference was found between preterm CP patients (n = 156) and preterm controls in males or between term and preterm CP patients in either males or females.

###### 

Allele and genotype distributions of the SNPs in male term cerebral palsy patients and controls

               **Group**     **Allele frequency**   ***P*value**        **Genotype frequency**  ***P*value**   **Hardy-Weinberg equilibrium**                         
  ------------ ------------- ---------------------- ------------------ ------------------------ -------------- -------------------------------- ------------- ------- -------
  rs1800796                  C                      G                                           C/C            C/G                              G/G                       
  Case         463 (0.689)   209 (0.311)            0.137                    162 (0.482)        139 (0.414)    35 (0.104)                       0.282          0.525  
               Control       617 (0.654)            327 (0.346)                                 20 (0.426)     215 (0.456)                      56 (0.119)             0.897
  rs2069837                  A                      G                                           A/A            A/G                              G/G                       
  Case         540 (0.811)   126 (0.189)            **0.012**^**a**^         220 (0.661)        100 (0.300)    13 (0.039)                       **0.046**      0.699  
               Control       702 (0.758)            224 (0.242)                                 272 (0.587)    158 (0.341)                      33 (0.071)             0.134
  rs2066992                  G                      T                                           G/G            G/T                              T/T                       
  Case         209 (0.312)   461 (0.688)            0.203                     33 (0.099)        143 (0.427)    159 (0.475)                      0.430          0.918  
               Control       323 (0.342)            621 (0.658)                                 54 (0.114)     215 (0.456)                      203 (0.430)            0.797
  rs2069840                  C                      G                                           C/C            C/G                              G/G                       
  Case         610 (0.905)   64 (0.095)             0.838                    276 (0.819)        58 (0.172)     3 (0.009)                        0.701          0.980  
               Control       859 (0.908)            87 (0.092)                                  388 (0.820)    83 (0.175)                       2 (0.004)              0.271
  rs10242595                 A                      G                                           A/A            A/G                              G/G                       
  Case         595 (0.891)   73 (0.109)             0.544                    266 (0.796)        63 (0.189)     5 (0.015)                        0.769          0.570  
               Control       821 (0.881)            111 (0.119)                                 365 (0.783)    91 (0.195)                       10 (0.021)             0.134

^a^After the SNPSpD correction, the *P* value is 0.036.

Differences in genotype frequencies were observed between CP patients with maternal PROM (n = 88) and controls (n = 753) for rs2066992 and rs1800796 (Table [10](#T10){ref-type="table"}). Further analysis according to the sex of the CP patients showed differences between CP patients with maternal PROM (n = 88) and controls (n = 491) in males for rs2066992 and rs1800796, but the differences disappeared after SNPSpD correction.

###### 

Allele and genotype distributions of the SNPs in patients with or without maternal premature rupture of membrane (PROM)

               **Group**      **Allele frequency**   ***P*value**    **Genotype frequency**  ***P*value**   **Hardy-Weinberg equilibrium**                                           
  ------------ -------------- ---------------------- -------------- ------------------------ -------------- -------------------------------- ------------------ -------------------- -------
  rs1800796                   C                      G                                       C/C            C/G                              G/G                                         
  CP + PROM    121 (0.695)    53 (0.305)             0.504                 49 (0.563)        23 (0.264)     15 (0.172)                       **0.006**^**a**^          0.001         
  CP − PROM    856 (0.689)    386 (0.311)            0.292                298 (0.480)        260 (0.419)    63 (0.101)                       0.560                     0.572         
               Control        992 (0.670)            488 (0.330)                             334 (0.451)    324 (0.438)                      82 (0.111)          **0.011\***^**b**^   0.797
  rs2069837                   A                      G                                       A/A            A/G                              G/G                                         
  CP + PROM    145 (0.824)    31 (0.176)             0.171                 62 (0.705)        21 (0.239)     5 (0.057)                        0.231                     0.095         
  CP − PROM    993 (0.805)    241 (0.195)            0.101                407 (0.660)        179 (0.290)    31 (0.050)                       0.243                     0.056         
               Control        1134 (0.779)           322 (0.221)                             448 (0.615)    238 (0.327)                      42 (0.058)                               0.169
  rs2066992                   G                      T                                       G/G            G/T                              T/T                                         
  CP + PROM    54 (0.307)     122 (0.693)            0.609                 15 (0.170)        24 (0.273)     49 (0.557)                       **0.005**^**c**^          0.001         
  CP − PROM    387 (0.312)    855 (0.688)            0.425                 62 (0.100)        263 (0.424)    296 (0.477)                      0.663                     0.750         
               Control        483 (0.326)            999 (0.674)                             77 (0.104)     329 (0.444)                      335 (0.452)         **0.012\***^**d**^   0.775
  rs2069840                   C                      G                                       C/C            C/G                              G/G                                         
  CP + PROM    163 (0.926)    13 (0.0734             0.377                 75 (0.852)        13 (0.148)     0 (0.000)                        0.607                     0.454         
  CP − PROM    1137 (0.911)   111 (0.089)            0.635                516 (0.827)        105 (0.168)    3 (0.005)                        0.889                     0.339         
               Control        1346 (0.906)           140 (0.094)                             607 (0.817)    132 (0.178)                      4 (0.005)                                0.265
  rs10242595                  A                      G                                       A/A            A/G                              G/G                                         
  CP + PROM    153 (0.879)    21 (0.121)             0.915                 68 (0.782)        17 (0.195)     2 (0.023)                        0.990                     0.459         
  CP − PROM    1102 (0.893)   132 (0.107)            0.371                492 (0.797)        118 (0.191)    7 (0.011)                        0.395                     0.980         
               Control        1279 (0.882)           171 (0.118)                             569 (0.785)    141 (0.194)                      15 (0.021)                               0.079

\*Comparison between total CP patients with maternal PROM and without PROM.

^a^After the SNPSpD correction, the *P* value is 0.0018.

^b^After the SNPSpD correction, the *P* value is 0.033.

^c^After the SNPSpD correction, the *P* value is 0.015.

^d^After the SNPSpD correction, the *P* value is 0.036.

IL-6 quantification
-------------------

The mean plasma IL-6 concentration was higher in the CP patients than in the controls, and this difference was more pronounced in males (Figure [1](#F1){ref-type="fig"}A). Subgroup analysis showed that the IL-6 level was higher in the spastic CP group compared to the control group (Figure [1](#F1){ref-type="fig"}B). Furthermore, the IL-6 level in the CP patients was related to gestational age and a significant increase was seen in the full-term birth CP patients (Figure [1](#F1){ref-type="fig"}C). However, the IL-6 level was not changed compared to controls in the CP patients with PVL (Figure [1](#F1){ref-type="fig"}D). Further statistical analyses stratified by birth weight, birth asphyxia, MR, HIE, and maternal complications such as PIH, TPL, and PROM were also performed but no differences were found (data not shown). Furthermore, the plasma IL-6 levels were different between CP patients with genotypes CC and those with GG at rs1800796 (*P* = 0.033) (Figure [2](#F2){ref-type="fig"}A), and the plasma IL-6 levels of genotype CC at rs1800796 (Figure [2](#F2){ref-type="fig"}A), AA at rs2069837 (Figure [2](#F2){ref-type="fig"}B), and TT at rs2066992 (Figure [2](#F2){ref-type="fig"}C) in CP patients were higher than in their respective controls. Therefore, we have sufficient evidence to assume that there is a positive association of the IL-6 gene with the etiology of CP.

![**Plasma IL-6 concentrations in CP patients and controls. (A)** Distribution of plasma IL-6 concentrations between total CP patients (85 patients) and total controls (75 participants) and between subgroups analyzed by sex. **(B)** Plasma IL-6 concentrations among spastic CP patients (58 patients), non-spastic CP patients (27 patients), and controls. **(C)** Plasma concentrations among term CP patients (56 patients), preterm CP patients (29 patients), and controls. **(D)** Plasma IL-6 concentrations among CP patients with PVL (17 patients), CP patients without PVL (68 patients), and controls. Each dot represents one patient and each bar represents the mean value. \**P* \<0.05; Mann-Whitney U-test. CP, cerebral palsy; PVL, periventricular leukomalacia.](1742-2094-11-100-1){#F1}

![**Comparison of genotypes and plasma IL-6 levels in CP patients and controls. (A)** The comparison at rs1800796. **(B)** The comparison at rs2069837. **(C)** The comparison at rs2066992. Each dot represents one patient and each bar represents the mean value. \**P* \<0.05; Mann-Whitney U-test. CP, cerebral palsy.](1742-2094-11-100-2){#F2}

Discussion
==========

IL-6 is a proinflammatory cytokine that plays a key role in systemic inflammatory processes and has been identified as an important mediator of prenatal inflammation and CP. Clinical studies suggest that preterm neonates born to mothers with elevated IL-6 levels in the amniotic fluid are at increased risk for the subsequent development of PVL and CP \[[@B21]\], and CP patients show higher IL-6 levels in the cerebral spinal fluid \[[@B22]\]. Furthermore, infection has been shown to be an independent risk factor for spastic hemiplegia CP in infants born at term \[[@B23]\] and chorioamnionitis has been shown to be the most common cause of spastic quadriplegia CP \[[@B24]\]. In this study, we found that the plasma IL-6 levels were higher in CP patients than in controls and that IL-6 levels increased dramatically in spastic CP patients, which has not previously been reported. Overall, the findings from previous studies and our current work suggest that IL-6 is strongly associated with CP. Although we could not confirm whether the elevation of IL-6 levels is a recurrent or persistent issue that occurs after the event that led to the development of CP or if it is a transient effect during the late stage of CP; such increases might help to identify infants that could possibly benefit from later therapeutic interventions.

Genetic regulation of inflammation is an important biological risk factor that might contribute to the risk of developing CP \[[@B13]\]. The promoter region polymorphism rs1800795 (G-174C) in the *IL-6* gene has been associated with CP in populations from both Australia \[[@B8]\] and California \[[@B12]\]. The variant C allele of rs1800795 (G-174C) has been shown to markedly increase the risk of hemiplegic CP and quadriplegic CP in infants \[[@B8]\], and the CC genotype of the 174C/G variation is related to higher levels of IL-6 compared to the GG genotype \[[@B25]\].

Studies of *IL-6* polymorphisms have mainly focused on rs1800795 \[[@B8],[@B12]\], but this polymorphism is absent in the Han Chinese population \[[@B26]\]. The SNPs rs1800796, rs2069837, and rs10242595 have all been reported to be associated with Alzheimer's disease and ischemic stroke \[[@B27]-[@B30]\], and the rs2069840 SNP has been shown to be associated with systemic sclerosis \[[@B31]\]. The common haplotype tagged by the SNP rs1800796 (C-572G) has been shown to be associated with an increased risk of brain infarct in elderly subjects in a cardiovascular health study \[[@B32]\]. Even though these SNPs were associated with neurological disease in adults, so far there has been no evidence showing an association with CP. This study has, for the first time, shown that associations between *IL-6* polymorphisms and CP are related to sex, PVL, gestational age, and the clinical subtype of CP. The rs2069837 SNP is associated with male spastic CP patients born at full term, and the genotypes of rs1800796 and rs2066992 are associated with male CP patients with PVL.

The genotypes produced from rs1800796 and rs2066992 SNPs, however, showed deviation from HWE in CP patients with PVL. Deviations from HWE could point to a sampling bias, mistyping of genotypes, or spurious gene associations after population stratification \[[@B33]\]. We carefully re-analyzed the data based on the reasons mentioned above and found that all of the controls were in HWE. As Esser suggested, if only the genotype distribution of the patient group shows deviation from HWE, this might provide additional support for an association between the marker locus with the disease in question \[[@B33]\]. Therefore, our study showed that the genotypes produced from the two SNPs (rs1800796 and rs2066992) are more likely associated with male CP patients with PVL. On the other hand, we cannot exclude the potential problem of a small sample size (n = 56) after population stratification.

In addition to changes in SNP frequency, we also measured IL-6 levels directly and found that in CP patients the CC genotype of rs1800796 (C-572G) has an effect on serum levels of IL-6 compared to the GG genotype. This is similar to what has been seen in trauma patients carrying the −572 C allele or −572 G allele \[[@B34]\]. This suggests that the G allele of rs1800796 could reduce transcriptional activity of the IL-6 promoter. We also found that the plasma IL-6 levels of genotype CC at rs1800796, AA at rs2069837, and TT at rs2066992 in CP patients were higher than their respective controls. We speculate that the genetic variation might enhance or weaken the inflammatory response to some extent during the pathogenic process of CP, or it might influence the interaction between genetic factors and the environment. It seems that the C allele of rs1800796, the A allele of rs2069837, and the T allele of rs2066992 might be risk factors for CP. This must be further confirmed with even larger samples.

In this study population, 69.3% (494/713) of the CP patients were males, and this proportion is in accordance with reports from other nations \[[@B35]-[@B38]\]. This sex-related difference has also been noticed in *in vitro* and *in vivo* models of cerebral ischemia and neuronal injury \[[@B39]\]. However, even though sex hormones, such as estrogens, protect against brain injury \[[@B40]\], the circulating hormone levels cannot completely account for sex differences in the CP patients or in the developing brain \[[@B41]\]. This could be related to genetic background since it has been reported that female-derived neurons (XX) have a survival advantage compared with male-derived neurons (XY) \[[@B42]\].

PROM has been associated with increased risk for intrauterine infection and clinical chorioamnionitis \[[@B43],[@B44]\], and it has been observed that infants born after PROM are at increased risk of white matter injury and subsequent CP diagnosis \[[@B45],[@B46]\]. In our study, we found that the genotypes of SNPs rs1800796 and rs2066992 are associated with CP and that this association is more robust in CP patients with maternal PROM. This finding suggests that maternal infections can be an up-stream causative factor that contributes to CP.

In summary, our study suggests that IL-6 participates in the pathogenesis of CP in a sex-related manner and that *IL-6* gene polymorphisms are risk markers for male term infants and might be related to the development of PVL in male CP patients.
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